Odds of Anxiety, Depression, ADHD Up With Congenital Heart Disease
Youth with congenital heart disease have increased odds of anxiety and/or depression or ADHD, regardless of disease severity,
ADHD Information Center
BMI, Neuroticism, and Conduct Problems Associated With Future Eating Disorders
Researchers conducted a population-based, longitudinal cohort study of data from adolescent participants in the IMAGEN Study, seeking to identify early associations with the development of eating disorders.
Gestational Age Tied to Attention-Deficit Symptoms With Down Syndrome
Gestational age is associated with symptoms of ADHD in late‑preterm to full‑term children and adolescents with Down syndrome.
Review Assesses Pharmacotherapies for Adult ADHD
The review included a total of 81 unique trials that reported 1 or more outcomes of interest.
ADHD Prevalence Higher Among African Americans Compared With US Population
Black individuals may be at higher risk for attention-deficit/hyperactivity disorder than the general US population.
Identifying Diagnostic Bias to Improve Outcomes of Women With ADHD
Women are 3 times more likely to be treated for a mood disorder, depression, or anxiety than for ADHD compared with men.
Comorbid ADHD More Prevalent in Boys, Adolescents With Autism Spectrum Disorder
A retrospective study was conducted to evaluate the demographic predictors of ADHD in hospitalized children with ASD and the impact of comorbidities on length of stay.
Novel Stimulant Effective for Adult ADHD, Regardless of Prior Stimulant Exposure
SHP465 mixed amphetamine salts reduced symptoms of attention-deficit/hyperactivity disorder in adults, independent of ADHD treatment history.
Investigational Stimulant Found Effective, Safe for Treatment of ADHD Symptoms in Adults
Investigators conducted a randomized clinical trial to assess the safety and efficacy of the investigational stimulant AR19 for the treatment of symptoms of attention-deficit/hyperactivity disorder in adults.
Adult ADHD Symptoms May Predict Motor Vehicle Crash Risk
Having ADHD symptoms that persist into adulthood is associated with a higher risk for being involved in a motor vehicle crash.
Insomnia and Alcohol Consumption Linked to ADHD Symptoms
Among adults without a clinical diagnosis of ADHD, heavy alcohol use predicted more severe ADHD symptoms.
Stigmas Identified in Nurse Practitioners’ Attitudes Toward Managing Mental Health Conditions
Researchers conducted a cross-sectional study to assess nurse practitioners’ attitudes and beliefs regarding working with individuals with a mental health disorder.
Study Supports Using WURS and ASRS Jointly to Assess Adult ADHD
In this study, researchers sought to investigate the psychometric properties of the ASRS and WURS in a well-characterized sample of adult ADHD patients and population controls.
FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Low Maternal Vitamin D May Raise Risk for ADHD in Offspring
Study looked at maternal serum vitamin D levels in first trimester and offspring ADHD risk.
UK Study Finds Regional Variation in Prescription, Referral Patterns for ADHD
The percentage of patients with an ADHD prescription between their 16th and 19th birthdays decreased by 19% in all patients.
Recommendations Developed for Management of Complex ADHD
Treatment should include evidence-based approaches and account for coexisting conditions.
Effects of Omega-3 Fish Oil Mixed for ADHD Symptoms in Youth
Supplements may not improve cognitive symptoms in youth who have high endogenous EPA levels.
Behavioral Interventions Beneficial for ADHD
Researchers sought to identify the major leading nonpharmaceutical intervention for ADHD cognitive symptomology, as well as which cognitive symptoms are most amenable to change.
Viloxazine NDA Submitted for Review as Potential New ADHD Treatment
The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ADHD Information Center
